NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis: Implications for mechanism of bone formation inhibition in man

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 3, 2011, Pages 525-534

  Pountos, Ippokratis ^a   Giannoudis, Peter V ^a   Jones, Elena ^a   English, Anne ^a   Churchman, Sarah ^a   Field, Sarah ^a   Ponchel, Frederique ^a   Bird, Howard ^a   Emery, Paul ^a   Mcgonagle, Dennis ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Bone healing; COX 1; COX 2; MSCs; NSAIDs

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLYCOSAMINOGLYCAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE; BONE DEVELOPMENT; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; DRUG EFFECT; FEMALE; GENETICS; HUMAN; MALE; MESENCHYMAL STEM CELL; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE AND BONES; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHONDROGENESIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; OSTEOGENESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 79953319215     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01006.x     Document Type: Article

References (55)

1. Rihn JA, Gates C, Glassman SD, et al The use of bone morphogenetic protein in lumbar spine surgery. J Bone Joint Surg Am. 2008; 90: 2014-25.
2. Pountos I, Giannoudis PV. Biology of mesenchymal stem cells. Injury. 2005; 36: S8-12.
3. Reuben SS, Ablett D, Kaye R. High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Can J Anaesth. 2005; 52: 506-12.
4. Reuben SS, Ekman EF. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am. 2005; 87: 536-42.
5. Glassman SD, Rose SM, Dimar JR, et al The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine. 1998; 23: 834-8.
6. Pountos I, Georgouli T, Blokhuis TJ, et al Pharmacological agents and impairment of fracture healing: what is the evidence Injury. 2008; 39: 384-94.
7. Reuben SS, Fingeroth R, Krushell R, et al Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty. 2002; 17: 26-31.
8. Gajraj NM. The effect of cyclooxygenase-2 inhibitors on bone healing. Reg Anesth Pain Med. 2003; 28: 456-65.
9. Beck A, Salem K, Krischak G, et al Nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing. Oper Orthop Traumatol. 2005; 17: 569-78.
10. Zhang X, Schwarz EM, Young DA, et al Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002; 109: 1405-15.
11. Ma YF, Li XJ, Jee WS, et al Effects of prostaglandin E2 and F2 alpha on the skeleton of osteopenic ovariectomized rats. Bone. 1995; 17: 549-54.
12. Weinreb M, Suponitzky I, Keila S. Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone. 1997; 20: 521-526.
13. Paralkar VM, Grasser WA, Mansolf AL, et al Regulation of BMP-7 expression by retinoic acid and prostaglandin E(2). J Cell Physiol. 2002; 190: 207-17.
14. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol. 2004; 200: 400-6.
15. Brown KM, Saunders MM, Kirsch T, et al Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am. 2004; 86: 116-23.
16. Yamakawa K, Kamekura S, Kawamura N, et al Association of microsomal prostaglandin E synthase 1 deficiency with impaired fracture healing, but not with bone loss or osteoarthritis, in mouse models of skeletal disorders. Arthritis Rheum. 2008; 58: 172-83.
17. Seibert K, Zhang Y, Leahy K, et al Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994; 25: 12013-7.
18. Dubois RN, Abramson SB, Crofford L, et al Cyclooxygenase in biology and disease. FASEB J. 1998; 12: 1063-73.
19. Davis TR, Ackroyd CE. Non-steroidal anti-inflammatory agents in the management of Colles' fractures. Br J Clin Pract. 1988; 42: 184-9.
20. Adolphson P, Abbaszadegan H, Jonsson U, et al No effects of piroxicam on osteopenia and recovery after Colles' fracture. A randomized, double-blind, placebo-controlled, prospective trial. Arch Orthop Trauma Surg. 1993; 112: 127-30.
21. Wurnig C, Schwameis E, Bitzan P, et al Six-year results of a cementless stem with prophylaxis against heterotopic bone. Clin Orthop Relat Res. 1999; 361: 150-8.
22. Giannoudis PV, MacDonald DA, Matthews SJ, et al Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000; 82: 655-8.
23. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop. 1998; 355S: 7-21.
24. Bain BJ. Bone marrow aspiration. J Clin Pathol. 2001; 54: 657-63.
25. Noth U, Osyczka AM, Tuli R, et al Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. J Orthop Res. 2002; 20: 1060-9.
26. Sakaguchi Y, Sekiya I, Yagishita K, et al Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood. 2004; 104: 2728-35.
27. Tuli R, Seghatoleslami MR, Tuli S, et al A simple, high-yield method for obtaining multipotential mesenchymal progenitor cells from trabecular bone. Mol Biotechnol. 2003; 23: 37-49.
28. ABPI. Compedium of data sheets and summaries of product characteristics. London ABPI Datapharm; 2009.
29. Hynninen VV, Olkkola KT, Bertilsson L, et al Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. Antimicrob Agents Chemother. 2009; 53: 587-92.
30. Rose P, Steinhauser C. Comparison of lornoxicam and rofecoxib in patients with activated osteoarthritis. Clin Drug Invest. 2004; 24: 227-236.
31. McEvoy GK. AHFS Drug Information. Bethesda: Amer Soc of Health System; 2004. pp. 534-720.
32. Hardman J, Limbird L. The pharmacological basis of therapeutics. New York McGraw-Hill; 2001. pp. 643-87.
33. Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet. 1999; 36: 115-26.
34. Jones EA, Kinsey SE, English A, et al Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 2002; 46: 3349-60.
35. Mackay AM, Beck SC, Murphy JM, et al Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng. 1998; 4: 415-28.
36. Seibert K, Zhang Y, Leahy K, et al Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994; 25: 12013-7.
37. Ali M, Ponchel F, Wilson KE, et al Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. J Clin Invest. 2001; 107: 519-28.
38. Wolfesberger B, Hoelzl C, Walter I, et al In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther. 2006; 29: 15-23.
39. Sell S, Teschner M, Gaissmaier C, et al Effect of diclofenac on human osteoblasts and their stromal precursors in vitro in relation to arthroplasty. Z Rheumatol. 1999; 58: 13-20.
40. Ho ML, Chang JK, Chuang LY, et al Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol. 1999; 58: 983-90.
41. Chang JK, Wang GJ, Tsai ST, et al Nonsteroidal anti-inflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect Tissue Res. 2005; 46: 200-10.
42. Evans CE, Butcher C. The influence on human osteoblasts in vitro of non-steroidal anti-inflammatory drugs which act on different cyclooxygenase enzymes. J Bone Joint Surg Br. 2004; 86: 444-9.
43. Garavito RM, DeWitt DL. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta. 1999; 23: 278-87.
44. Boursinos LA, Karachalios T, Poultsides L, et al Do steroids, conventional non-steroidal anti-inflammatory drugs and selective COX-2 inhibitors adversely affect fracture healing J Musculoskelet Neuronal Interact. 2009; 9: 44-52.
45. Rice PL, Goldberg RJ, Ray EC, et al Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001; 61: 1541-7.
46. Ou YC, Yang CR, Cheng CL, et al Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol. 2007; 563: 49-60.
47. Ho CC, Yang XW, Lee TL, et al Activation of p53 signalling in acetylsalicylic acid-induced apoptosis in OC2 human oral cancer cells. Eur J Clin Invest. 2003; 33: 875-82.
48. Baek SJ, Kim JS, Moore SM, et al Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol. 2005; 67: 356-64.
49. Wahl C, Liptay S, Adler G, et al Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998; 101: 1163-74
50. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008; 27: 5527-41.
51. Jakob M, Demarteau O, Suetterlin R, et al Chondrogenesis of expanded adult human articular chondrocytes is enhanced by specific prostaglandins. Rheumatology. 2004; 43: 852-7.
52. Bassleer C, Magotteaux J, Geenen V, et al Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology. 1997; 54: 49-56.
53. Bassleer C, Henrotin Y, Franchimont P. Effects of sodium naproxen on differentiated human chondrocytes cultivated in clusters. Clin Rheumatol. 1992; 11: 60-5.
54. Zhang X, Schwarz EM, Young DA, et al Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002; 109: 1405-15.
55. Karachalios T, Boursinos L, Poultsides L, et al The effects of the short-term administration of low therapeutic doses of anti-COX-2 agents on the healing of fractures. An experimental study in rabbits. J Bone Joint Surg Br. 2007; 89: 1253-60.